NCT03824704View on ClinicalTrials.gov

A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

August 23, 2019

Primary Completion Date

August 24, 2020

Study Completion Date

August 24, 2020

Conditions
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal CarcinomaHigh Grade Serous CarcinomaEndometrioid Adenocarcinoma
Interventions
DRUG

Rucaparib

Oral rucaparib will be administered twice daily

DRUG

Nivolumab

IV nivolumab will be administered once every 4 weeks

Trial Locations (5)

31404

Memorial Health University Medical Center, Savannah

70433

Women's Cancer Care, Covington

73104

Stephenson Cancer Center, Oklahoma City

93611

Community Cancer Institute, Clovis

05041

University of Vermont Medical Center, Burlington

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Foundation Medicine

INDUSTRY

lead

pharmaand GmbH

INDUSTRY

NCT03824704 - A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | Biotech Hunter | Biotech Hunter